Two-stage deployment aneurysm embolization devices

Information

  • Patent Grant
  • 9393022
  • Patent Number
    9,393,022
  • Date Filed
    Thursday, August 8, 2013
    11 years ago
  • Date Issued
    Tuesday, July 19, 2016
    8 years ago
Abstract
Embolic implants, delivery systems and methods of manufacture and delivery are disclosed. The subject implants are deployed in two stages. If sized properly as observed in the first stage, they are deployed to the second stage and detached. If not sized properly in/at the first stage, the implants are designed to be withdrawn and replaced with a more appropriately sized implant or another treatment option selected. Some of the implant configurations may be withdrawn even after the second stage deployment as well.
Description
BACKGROUND

Numerous companies have pursued ball-type embolization devices for aneurysm treatment. Many of these, including the Nfocus LUNA device and other embodiments disclosed in commonly-owned patent applications are designed to be sized to fit a given aneurysm when the implant is fully deployed outside a delivery catheter. The same is true for the braid-ball implants disclosed and produced by Sequent Medical, Inc.


At least with the LUNA device, if size as visualized upon deployment (under active x-ray—i.e., “medical imaging”) is acceptable to a physician, the implant is detached. If not, the device is retrieved and exchanged for a more appropriate size. No example of devices designed for intra-aneurysmal treatment are known in which confirmation of final sizing is accomplished under medical imaging where the implant is deployed only up to a pre-selected or identified point. Certainly, embolization coils are often partially deployed within an aneurysm and visualized to determine if their size and/or configuration is acceptable before further advancing the same and effecting release. However, these are not deployed to a specified point as marked on the delivery system for making a size check.


SUMMARY

Generally, braid-balls for aneurysm or other embolization through blood flow disruption and thrombus formation are described. More specifically, variations of the invention concern a subject hub region architecture that may be employed in a single-layer braid ball implant or a double-layer “LUNA” type (i.e., folded-over/flat) implant architecture.


In use, the bulb of the subject implant is deployed in an aneurysm with the estimated final position of the proximal end visualized by aligning a catheter marker with the device proximal end. The implant end may include a band or otherwise (such as by welding) serve as a hub to the braid from which the implant is constructed. Other options as described further below are disclosed as well.


Regardless, if the first stage/bulb “fits”, then the adjacent retracted hub region is fully deployed (i.e., the second stage is deployed) and the implant is released from its pusher. The position of the catheter shaft marker and shape of the (first) sizing stage of the implant may be selected from a number of options as shown and described, as well as others.


The shape in the hub region is preferably configured to provide force for self-actuation upon catheter exit. One advantageous configuration is substantially spherical. Another contemplated shape is defined by two conical bodies meeting around a common base. When inset in a more curvilinear (heart-shaped) in cross section, the deployed hub can provide additional blood flow satiation zone(s) within the implant.


In any case, the inset is provided such that it can retract even when the implant is compressed to fit a high aspect ratio aneurysm. As demonstrated, the implant is operable in a pocket simulating an aneurysm with a dome-to-width ratio of about 2:1. Based on the implant configuration, higher ratios will be possible as well.


The exemplary embodiment demonstrating such activity employs a small spherical inset region. The inset region was defined over a spherical ball about 3 mm in diameter, for an implant between at least about 6-7 mm in gross outside diameter. Thus, the nested inset region can fully expand even within the outer bulb when partially compressed. When using the double-cone shape for the inset region, the additional stored energy available at the medial crease can be of further assistance driving inset shape recovery. Moreover, the conical taper can provide improved clearance for full expansion of the inset form in cases where the outer body or bulb of the implant is further compressed.


The distal/terminal end of the implant and any associated proximal hub/band may be positioned at the periphery of the bulb of the implant when fully deployed, or more inset in varying degrees. When employed in a “LUNA” folded-flat configuration, the distal marker of the implant is internal and a tether extends to the proximal hub of the device. In a one-layer implementation (i.e., a configuration that presents one layer at the distal end of the implant with the option of more at a proximal side depending on inset shape configuration) the distal marker be provided by a radiopaque material (e.g., Pt) band capturing the braid. As to the proximal side of either such device, it may comprise a radiopaque band capturing the braid. As discussed in US Patent Application No. 2011/0319926 (Becking, et al.) another option is to remove the band after the braid has been glued to create a composite hub construct.


In yet another variation, no such hub or band is provided at the proximal end of the braid defining the implant. Instead, a length of braid (between about 1 and about 2 mm long) is employed as a delivery system interface. Such a “tail” or sleeve of braid, when confined within a catheter is able to firmly grip/interlock with a complementary delivery system surface. In such a system, the delivery system surface is also advantageously covered or constructed of braid of a similar wire size and configuration to promote interlocking. Once the implant is free of the catheter, the (formerly) confined sleeve of braid defining the implant tail opens to permit the inner delivery system pusher member to be pulled free.


The forming method for a LUNA-style hidden hub implant is detailed herein in two heatsetting stages. Stage 1 produces a double-layer “folded-flat” implant preform with a columnar inset. Stage 2 changes the shape of the inset into a spherical volume. In the second forming and heatsetting procedure, a proximal suture tie may be employed in defining a second folded-flat region like that at the distal side as formed in Stage 1. The second heatsetting cycle may also be employed to modify the shape of the outer bulb. For example, while retaining the “folded-flat” distal bend(s), the gross shape of the bulb may be compressed from a substantially cylindrical shape to a more squat or flattened “M&M” shape (e.g., ellipsoidal). So-shaped, greater radial force is available for aneurysm fit and/or a greater range of treatment sites made available. Further reference to heatsetting methodology and delivery systems as may be applied to the present invention are presented in U.S. patent application Ser. No. 12/465,475 and PCT/US2009/041313 and U.S. patent application Ser. No. 12/942,209 and PCT/US2010/56051, each incorporated by reference in its entirety.


Other manufacture techniques are applicable as well. For instance, a selective heat treatment approach is contemplated in which a portion of the implant performing being shaped is set over a ferromagnetic material (e.g., 304 magnetic stainless steel alloy) and is heated through induction utilizing a radio-frequency (RF) field. Such an approach strictly localizes the heat treatment to areas in contact with the induction-heated element. To insure that no other material is significantly heat-affected, such activity may be conducted under the flow of coolant such as Nitrogen or Argon gas or some other medium. In any case, such an approach may be advantageously used in the “Stage 2” operation described above for re-shaping the inset region, without applying a second heat treat to the remainder of the implant preform.


The body of the subject implants may be constructed of NiTi alloy that is superelastic at human body temperature. Advantageously, the wire is in the size range of 0.0008 to 0.0013 inches, although it may be larger or smaller. It may be etched pre- and/or post-heat treatment using AYA solution or by such processes employed by service providers including NDC, Inc. Binary Nitinol alloy may be employed, or the alloy may include Au, Pt, W, Ir, Pd, alloys thereof or another dense element to improve radiopacity. Another approach to improving radiopacity contemplates using a plurality of such wires or ribbons intermixed when braiding with Nitinol. Otherwise, Pt core Nitinol Drawn Filled Tube (DFT) may be employed or other means.


The braid matrix is particularly effective in promoting thrombosis in order to embolize an aneurysm as its density increases. For a given catheter crossing profile, a certain maximum braid configuration is possible. For example, “folded-flat” implants as further described herein that are intended to track to the neurovasculature through commercially available 3 Fr/0.027 inch catheters (such as the REBAR or MARKSMAN) may be constructed from a 72×0.001″ braid configuration (as originally provided or etched thereto) or 96×0.0009″ braid (ditto) configuration. In single layer implant architectures, 144-end braid configurations are feasible with similar crossing profile with wire size in the range of about 0.008 to about 0.0011 inches in diameter. Still, it is to be noted that higher end count braid (e.g., 192 or 288) can be employed in the subject invention as can other braid end multiples/configurations. Likewise, it is possible to construct braided implants indented for 0.021 inch catheter compatibility. These may advantageously use two layers of 48×0.001″ braid or higher “end” multiple counts in thinner wire/filament or single-layer 72 or 96 end braid selections, etc.


In any case, the subject inventions include the devices, kits in which they are included, methods of use and methods of manufacture. More detailed discussion is presented in connection with the figures below.





BRIEF DESCRIPTION OF THE FIGURES

The figures provided herein are not necessarily drawn to scale, with some components and features exaggerated for clarity. Variations of the invention from the embodiments pictured are contemplated. Accordingly, depiction of aspects and elements of the invention in the figures are not intended to limit the scope of the invention.



FIG. 1 illustrates a variation of the subject implant deployed in an side-wall aneurysm model;



FIGS. 2A and 2B and FIGS. 3A and 3B diagrammatically illustrate an implant in use with coordinated catheter systems at different first and second stages of implant deployment, respectively;



FIGS. 4A-4D illustrate the implant construction from FIG. 1 visualized through a clear catheter in the stages of deployment represented in FIGS. 2A-3B;



FIGS. 5A-5F illustrate inset configuration variations;



FIGS. 6A-6C illustrate deployment of an implant with a hubless delivery system interface employing yet another inset configuration;



FIGS. 7A-7D illustrate stages of implant production; and



FIG. 8 is a flowchart showing various implant manufacture options.





DETAILED DESCRIPTION

Various exemplary embodiments of the inventive aspects are described below. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the subject inventions. Various changes may be made to the subject matter described and equivalents may be substituted without departing from the true spirit and scope of the invention(s).


Aneurysm Embolization Systems


The embodiments described herein are specifically designed so that, when deployed to a given stage within an aneurysm, the size of this stage is representative of the final size and configuration of the implant upon final deployment with the delivery system. Several advantages can be achieved in conjunction with such a system. One such advantage involves the opportunity to minimize delivery profile and/or complexity given the unique implant/delivery system interaction enabled. Another advantage involves the opportunity to provide larger implant sizes for a given delivery profile. Still another set of advantages involves the ease of expanded implant recapture, together with associated procedural and patient safety advantages. All told, aspects of the present invention (alone and/or in combination with one another) provide for a new and useful system for neurovascular aneurysm treatment or for treating other vascular, pocket-type or luminal defects.



FIG. 1 shows an implant 10 delivered according to the subject methodology as deployed in an side-wall aneurysm model 2. The model includes a parent vessel 4 and aneurysm fundus 6 filled by the implant 10. The implant is delivered in association (preferably via a detachable association vs. simple abutment) with a pusher 20. The implant comprise an outer bulb 12 and a substantially spherical inset region 14. A dense and complex structure is thus presented to the direction of blood flow (as indicated by arrows) to help promote blood thrombosis via disruption of its flow. Markers are optionally present at proximal and distal extents 16, 18 of the implant.



FIGS. 2A and 2B and FIGS. 3A and 3B diagrammatically illustrate the implant in use with coordinated catheter systems. FIGS. 2A and 2B illustrate one optional approach to staged deployment; FIGS. 3A and 3B illustrate another. All of these figures illustrate a generic distal implant architecture 30 in which a distal marker 32 diagrammatically pictured. In each view, the implant includes a proximal hub/marker band 34 operating as an interface region to an (optionally detachable) pusher 40. The hub and pusher may be connected by a mechanical detachment interface as described in the above-referenced patent applications, an electrolytically-severable joint, a meltable polymer filament, etc. In any case, the pusher is shown within the end of a microcatheter 50. The microcatheter includes a distal marker 52 and a more proximal reference marker 54.


In FIG. 2A, the reference marker is set at a position such that when the implant proximal hub/marker 34 is aligned therewith the freed/expanded portion of the implant is deployed in a “teardrop” of approximately the same height of the finally deployed implant shape as shown in FIGS. 2B and 3B. Likewise, the catheter reference marker shown 54′ in FIG. 3A is positioned such that a “mushroom” shape with flats 36 is produced upon hub 34 alignment therewith. Again, this intermediate implant body shape is similarly sized to the finally delivered implant configuration.


As such, at either intermediate stage of delivery (i.e., in a system configured per FIG. 2A, 3A or related thereto) a physician can determine if the implant is the proper size selected for the aneurysm to be treated by visualizing the position of the distal marker 32 in/on the implant and the distal marker 52 of the catheter. If the distal marker of the catheter is positioned at the neck of the aneurysm when the implant is in the first/intermediate stage of delivery, then the physician is offered an indication (mid-procedure) that upon completion of implant deployment that the proximal surface of the implant will be likewise so-positioned, as desired. Thus, an aspect of the invention concerns a catheter with a marker system and an implant (or an implant pusher as further described below) that include radiopaque markers coordinated for a first “check” stage of deployment followed by a “final” release/released deployment stage.



FIGS. 4A-4D illustrate the implant construction in stages of deployment visualized within a glass vial serving a second model 2′. The implant 30 is shown at various positions confined within a clear sheath 50′ simulating a catheter. Proximal to a marker element 34 seen in each image is a coil-reinforced length 22 simulating a pusher. FIG. 4A illustrates the implant in a first stage of the deployment of bulbous portion with the catheter end at point A. In FIG. 4B, the full-size teardrop sizing-check shape has developed with the catheter end at point B. With little or no substantial change in height, the mushroom sizing shape is developed with the catheter end at point B′. As evident from movement of marker 34, however, the pusher has been advanced. Upon advancement of the pusher and marker 34 to its ultimate/final position before pusher detachment, the final implant shape is formed with no significant difference in the position of the proximal face of the implant as evident by the alignment of the lead-line arrows.


Notably, all of the figures up to this point illustrate an inset region 14 configuration as shown in cross section per FIG. 5A. Likewise, FIG. 5A illustrates the manner in which the sizing of the inset region 14 accommodates different compression factors 30, 30′ of the same implant ball or bulb. The relatively small(er) spherical inset configuration in FIG. 5A is advantageously formed as further described below. Moreover, it demonstrates robust recovery and actuation as pictured. However, other inset shapes or forms offer further advantages and options as described below.


For example, FIG. 5B illustrates an inset 60 that is “heart shaped” in cross section. Such an inset offers additional clearance for bulb compression along a conical proximal section 62. Yet, the curve 64 to the distal section facilitates recapture of the device even after complete exit of extension 66 and hub 34 from the delivery catheter. By way of contrast, a double-conical shaped inset 70 as shown in FIG. 5C may “lock” with the catheter at the deeply inset “V” junction 72. Yet, the double-cone shape may be desirable because the increased number of sharp bends or transitions within the profile can help drive predictable shape recovery and increase resistance to radial compression within the proximal portion of the device.



FIG. 5D illustrates a second species of conical inset 74. In this variation, the two cones are adjacent, each with its own base 76, 76′ instead one that is conjoined. Further, FIG. 5D illustrates the manner in which any “tail” or extension section of the braid connecting to the hub 34 can be made short or essentially eliminated as compared to the previous variations. Moreover, the upper and lower cones are set at different angles so as to close the proximal end of the device at 78. Naturally, the previous inset variations can receive similar treatment as well.



FIG. 5E illustrates an approach in which the entry/exit port of the hub 34′ is inverted. Thus, recapture into a catheter requires a 180 degree bend form at the braid/hub junction. It will track the same way in the catheter for deployment. Such a feature may limit catheter downsizing. However, this feature can be accommodated by utilizing finer wire (e.g., 0.0008 inch diameter or less) able to bend in a tighter radius than heavier wire.


Again, the length or position of the inset extension 82 can be varied. For example, it may be desirable to extend it such that the position of the hub marker 34′ appears in roughly the center of implant 30 when uncompressed as illustrated in dashed line. Such an approach may be desirable when intending to fill a cavity with multiple numbers (e.g., in a multi-ball treatment approach to giant aneurysm) of the same implant that are allowed to fully expand, rather than form-fitting a single implant to fill an aneurysm. In which case, the hub can serve as a single, centrally-located marker.


Next, FIG. 5E illustrates an inset 90 that includes no hub and/or marker arrangement. Instead, this inset is configured especially for use with a delivery system as illustrated in FIGS. 6A-6C. Its shape is set to open when uncompressed by a catheter at bulb 92, while offering additional compression force at bends 94 for delivery system securement (via increased linear pressure) when the shape is compressed within the delivery catheter.


With respect to FIGS. 6A-6C, these illustrate an implant 30 with a urn or vase-shaped inset 100 as shown deployed/developed in FIGS. 6B and 6C. Such an inset offers advantageous proximal-side clearance, with a flat top 102 reducing inset height, and a distal crease 104 storing energy upon compression to drive shape recovery upon catheter release.


More generally, FIG. 6A illustrates implant 30 with bulb 12 outside of a delivery catheter 50 and implant tail 106 (before it transforms into the inset shape 100) still located therein. An interface segment 108 of the tail surrounds a textured (optionally by matching braid) retention section 120 of a pusher 122.


The whole length of the pusher may comprise metal braid which is encased/co-extruded by Polyimide with the distal section ablated from the braid. Components for such construction and ablation services are available from Microlumen, Inc. Tapered flex can be designed into the shaft by further selective ablation and/or including a taper-ground wire (floating or bonded) within a lumen of the pusher construction.


The delivery microcatheter includes a distal soft tip 56 and distal marker 52. A proximal reference marker 54 on the catheter is shown located between a pair of reference markers 110 on pusher 122. So long as the catheter holds the implant interface section compressed to the pusher retention section, the implant can be retrieved.


However, upon full deployment as shown in FIG. 6B, the interlocking interface between the implant and pusher is lost. At this point, pusher 122 may be withdrawn as shown in FIG. 6C and the catheter withdrawn as well. As positioned, the distal end of the catheter continues to mark the proximal position of the implant as the pusher is withdrawn, with only a small gap.


Also noteworthy is manner in which the inset may be shaped to facilitate implant release. As illustrated by dashed line of features 102′ and 108′ in FIG. 6C, the inset may be shaped to specifically pull-away from the pusher retention section upon exit from the delivery microcatheter.


Implant Manufacture


As referenced above, the subject implant architecture may be employed in a single layer braid ball implant or a double-layer LUNA type (folded-over/flat) approach. FIGS. 7A-7D illustrate aspects of manufacture in the latter case. Further details may be appreciated in reference to the application Ser. Nos. 12/465,475 and 12/942,209 and PCT/US2009/041313 and PCT/US2010/56051, each of which is incorporated by reference in its entirety.


As illustrated in FIG. 7A, a “Stage 1” or “Intermediate” state implant preform 200 can be shaped and heatset in association with internal heatsetting tooling element or form 210 and such other elements as described in the referenced descriptions with the addition of a deep columnar inset 202 formed with sleeve 212. With a close-fit relation between the layers of braid 230, 232 and the form elements 210, 212 tight radius bends are set at the turns 224 as indicated.


Once freed of the form elements as shown in FIG. 7B, preform 202 is better visualized as including a generally bulbous portion 204 along with inset 202 and extension or tail region 206. The depth “ID” of the inset is coordinated to facilitate its acceptance of a secondary internal form 214 as shown in FIG. 7C. With a tie 216 to hold it in place, the extent of the bulb 204 (shown as inverted sections 204FIG. 7C) can be reversed or “flipped” back into shape as shown in FIG. 7D.


With a mandrel 218 secured (e.g., by a metal tie 220) in position relative to form 214, a shoulder 222 can be used to compress a proximal fold 234 in the device, and a table or flat 222 can be used to compress the bulb against table element 224 into a modified shape (in this case more “squat” or ellipsoidal in cross-section) in a second heatsetting step to define a “Stage 2” of “Final” shape preform 200′.


Such a process flow path is illustrated as the left path in the flowchart of FIG. 8. Specifically, after forming the native braid (previously heatset or not) from which the implant is constructed over and within mandrel/form pieces at 300, the body is heatset at 302. Freed from the first set of heatsetting fixtures, it is optionally reshaped/reformed at 304, followed by a second overall heatsetting procedure 306. Finally, at 308, further processing such as optionally hubbing with marker bands, installing other marker features, hub welding, etc. is performed and then loading onto any optional delivery system pusher, onto packaging and sterilization as is common.


As an alternate flow path, after the first heatsetting and second shaping, only the inset is heatset at 306′. This can be accomplished as described above using a ferromagnetic material and induction field to concentrate heat for setting the shape of the braid in contact with element 214, for example.


Generally when the braid comprises Nitinol, any such heatsetting is accomplished between 500-550° C. for a period up to about 5 minutes. Such heating may be followed by quenching in water or be otherwise performed.


Regardless, it is further contemplated that the entire shaping of the implant may occur in one more complex cycle 310 in which each of the bulb and inset portions of the implant are formed simultaneously over a more complex set of nested forms. Such an approach may be especially viable when the implant only comprises a single layer of braid instead of also including a folded-flat distal section.


Variations


The subject methods may include each of the physician activities associated with implant positioning and release. As such, methodology implicit to the positioning and deployment of an implant device forms part of the invention. Such methodology may include placing an implant within a brain aneurysm, or at parent vessel targeted for occlusion, or other applications. In some methods, the various acts of implant introduction to an aneurysm or parent vessel are considered. More particularly, a number of methods according to the present invention involve the manner in which the delivery system operates in reaching a treatment site, for example. Other methods concern the manner in which the system is prepared for delivering an implant.


Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there is a plurality of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural references unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth in the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.


The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language. All references cited are incorporated by reference in their entirety. Although the foregoing invention has been described in detail for purposes of clarity of understanding, it is contemplated that certain modifications may be practiced within the scope of the appended claims.

Claims
  • 1. An aneurysm treatment system comprising: a catheter with a distal marker and a proximal reference marker;an implant pusher; andan implant connected to a distal end of the implant pusher and comprising a bulbous portion and a tail portion, the tail portion adapted to be received in a linear configuration within the catheter with a distal end of the tail portion being proximal to the bulbous portion when the implant is in an intermediate stage, the tail portion defining an inset within the bulbous portion when the implant is in a final stage,wherein at least one of the pusher and the implant comprises an implant marker, wherein when the implant marker is aligned with the proximal reference marker, the implant is in the intermediate stage with the bulbous portion of the implant deployed from the catheter, wherein, when the implant marker is aligned with the distal marker, the implant is in the final stage with the implant deployed from the catheter and the tail portion defining the inset within the bulbous portion, wherein the implant has a height that is approximately the same in the intermediate stage and in the final stage.
  • 2. The system of claim 1, wherein the bulbous portion has a teardrop shape in the intermediate stage.
  • 3. The system of claim 1, wherein the bulbous portion has a mushroom shape in the intermediate stage.
  • 4. The system of claim 1, wherein the inset is configured to be recapturable in clinical use.
  • 5. The system of claim 1, wherein the inset is configured so that it is not recapturable in clinical use.
  • 6. The system of claim 5, wherein the inset is substantially spherical.
  • 7. The system of claim 5, wherein the inset has an opposing cone shape.
  • 8. The system of claim 5, wherein the inset includes an inverted hub.
  • 9. The system of claim 5, wherein the inset includes no hub.
  • 10. The system of claim 9, wherein the inset is adapted to expand from a compressed conical shape.
  • 11. The system of claim 10, wherein the inset is adapted to expand into the bulbous portion.
RELATED APPLICATIONS

This application is a continuation of International Patent Application No. PCT/US20121024747, filed on Feb. 10, 2012, entitled TWO-STAGE DEPLOYMENT ANEURYSM EMBOLIZATON DEVICES, which claims the benefit of and priority to U.S. Provisional Application No. 61/441,845, filed on Feb. 11, 2011, the entire contents of each being incorporated by reference herein.

US Referenced Citations (477)
Number Name Date Kind
3108593 Glassman Oct 1963 A
4425908 Simon Jan 1984 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4655771 Wallsten Apr 1987 A
4768507 Fischell et al. Sep 1988 A
4921484 Hillstead May 1990 A
4998539 Delsante Mar 1991 A
5026377 Burton et al. Jun 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5104404 Wolff Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5158548 Lau et al. Oct 1992 A
5222971 Willard et al. Jun 1993 A
5250071 Palermo Oct 1993 A
5334210 Gianturco Aug 1994 A
5378239 Termin et al. Jan 1995 A
5405379 Lane Apr 1995 A
5425984 Kennedy et al. Jun 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5499981 Kordis Mar 1996 A
5527338 Purdy Jun 1996 A
5545208 Wolff et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5549635 Solar Aug 1996 A
5624461 Mariant Apr 1997 A
5634942 Chevillon et al. Jun 1997 A
5645558 Horton Jul 1997 A
5662703 Yurek et al. Sep 1997 A
5690671 McGurk et al. Nov 1997 A
5702419 Berry et al. Dec 1997 A
5713907 Hogendijk et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5728906 Eguchi et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5741333 Frid Apr 1998 A
5749891 Ken et al. May 1998 A
5749919 Blanc May 1998 A
5749920 Quiachon et al. May 1998 A
5766151 Valley et al. Jun 1998 A
5814062 Sepetka et al. Sep 1998 A
5830230 Berryman et al. Nov 1998 A
5846261 Kotula et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5879366 Shaw et al. Mar 1999 A
5908435 Samuels Jun 1999 A
5911731 Pham et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5925060 Forber Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar et al. Aug 1999 A
5935362 Petrick Aug 1999 A
5941249 Maynard Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5951599 McCrory Sep 1999 A
5957948 Mariant Sep 1999 A
5976162 Doan et al. Nov 1999 A
5980554 Lenker et al. Nov 1999 A
6001092 Mirigian et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6024756 Huebsch et al. Feb 2000 A
6033423 Ken et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6059813 Vrba et al. May 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6086577 Ken et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099526 Whayne et al. Aug 2000 A
6106530 Harada Aug 2000 A
6110191 Dehdashtian et al. Aug 2000 A
6123715 Amplatz Sep 2000 A
6139564 Teoh Oct 2000 A
6152144 Lesh et al. Nov 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6183495 Lenker et al. Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6221086 Forber Apr 2001 B1
6261305 Marotta et al. Jul 2001 B1
6280412 Pederson, Jr. et al. Aug 2001 B1
6306141 Jervis Oct 2001 B1
6309367 Boock Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6325820 Khosravi et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6332576 Colley et al. Dec 2001 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6368339 Amplatz Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6383174 Eder May 2002 B1
6391037 Greenhalgh May 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6428558 Jones et al. Aug 2002 B1
6443972 Bosma et al. Sep 2002 B1
6447531 Amplatz Sep 2002 B1
6454780 Wallace Sep 2002 B1
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6530934 Jacobsen Mar 2003 B1
6544278 Vrba et al. Apr 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6569179 Teoh et al. May 2003 B2
6579302 Duerig et al. Jun 2003 B2
6579303 Amplatz Jun 2003 B2
6585748 Jeffree Jul 2003 B1
6585756 Strecker Jul 2003 B1
6589256 Forber Jul 2003 B2
6589265 Palmer et al. Jul 2003 B1
6592605 Lenker et al. Jul 2003 B2
6599308 Amplatz Jul 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6605111 Bose et al. Aug 2003 B2
6607551 Sullivan et al. Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635069 Teoh et al. Oct 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6666882 Bose et al. Dec 2003 B1
6666883 Seguin et al. Dec 2003 B1
6669717 Marotta et al. Dec 2003 B2
6669721 Bose et al. Dec 2003 B1
6676696 Marotta et al. Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6682546 Amplatz Jan 2004 B2
6689150 VanTassel et al. Feb 2004 B1
6689486 Ho et al. Feb 2004 B2
6695876 Marotta et al. Feb 2004 B1
6698877 Urlaub et al. Mar 2004 B2
6699274 Stinson Mar 2004 B2
6709465 Mitchell et al. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6723112 Ho et al. Apr 2004 B2
6723116 Taheri Apr 2004 B2
6730108 Van Tassel et al. May 2004 B2
6746468 Sepetka et al. Jun 2004 B1
6746890 Gupta et al. Jun 2004 B2
6780196 Chin et al. Aug 2004 B2
6792979 Konya et al. Sep 2004 B2
6797083 Peterson Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
RE38653 Igaki et al. Nov 2004 E
6811560 Jones et al. Nov 2004 B2
6855153 Saadat Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
RE38711 Igaki et al. Mar 2005 E
6860893 Wallace et al. Mar 2005 B2
6936055 Ken et al. Aug 2005 B1
6949103 Mazzocchi et al. Sep 2005 B2
6949113 Van Tassel et al. Sep 2005 B2
6953472 Palmer et al. Oct 2005 B2
6979341 Scribner et al. Dec 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6994092 van der Burg et al. Feb 2006 B2
6994717 Konya et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7029487 Greene, Jr. et al. Apr 2006 B2
7033375 Mazzocchi et al. Apr 2006 B2
7048752 Mazzocchi et al. May 2006 B2
7063679 Maguire et al. Jun 2006 B2
7070607 Murayama et al. Jul 2006 B2
7070609 West Jul 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128736 Abrams et al. Oct 2006 B1
7169177 Obara Jan 2007 B2
7195636 Avellanet et al. Mar 2007 B2
7211109 Thompson May 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7244267 Huter et al. Jul 2007 B2
7261720 Stevens et al. Aug 2007 B2
7303571 Makower et al. Dec 2007 B2
7306622 Jones et al. Dec 2007 B2
7331980 Dubrul et al. Feb 2008 B2
7367985 Mazzocchi et al. May 2008 B2
7367986 Mazzocchi et al. May 2008 B2
7371250 Mazzocchi et al. May 2008 B2
7393358 Malewicz Jul 2008 B2
7404820 Mazzocchi et al. Jul 2008 B2
7410482 Murphy et al. Aug 2008 B2
7410492 Mazzocchi et al. Aug 2008 B2
7413622 Peterson Aug 2008 B2
7419503 Pulnev et al. Sep 2008 B2
7442200 Mazzocchi et al. Oct 2008 B2
7485088 Murphy et al. Feb 2009 B2
7556635 Mazzocchi et al. Jul 2009 B2
7566338 Mazzocchi et al. Jul 2009 B2
7569066 Gerberding et al. Aug 2009 B2
7572273 Mazzocchi et al. Aug 2009 B2
7572288 Cox Aug 2009 B2
7575590 Watson Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7608088 Jones et al. Oct 2009 B2
7621928 Thramann et al. Nov 2009 B2
7632296 Malewicz Dec 2009 B2
7670355 Mazzocchi et al. Mar 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678130 Mazzocchi et al. Mar 2010 B2
7682390 Seguin Mar 2010 B2
7691124 Balgobin Apr 2010 B2
7695488 Berenstein et al. Apr 2010 B2
7699056 Tran et al. Apr 2010 B2
7727189 VanTassel et al. Jun 2010 B2
7744583 Seifert et al. Jun 2010 B2
7744652 Morsi Jun 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7906066 Wilson et al. Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7955343 Makower et al. Jun 2011 B2
7972359 Kreidler Jul 2011 B2
7993364 Morsi Aug 2011 B2
RE42758 Ken et al. Sep 2011 E
8016869 Nikolchev Sep 2011 B2
8016872 Parker Sep 2011 B2
8062379 Morsi Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8142456 Rosqueta et al. Mar 2012 B2
8202280 Richter Jun 2012 B2
8221445 van Tassel et al. Jul 2012 B2
8261648 Marchand et al. Sep 2012 B1
8298257 Sepetka et al. Oct 2012 B2
8430012 Marchand et al. Apr 2013 B1
8454681 Holman et al. Jun 2013 B2
20010000797 Mazzocchi May 2001 A1
20010007082 Dusbabek et al. Jul 2001 A1
20010012949 Forber Aug 2001 A1
20010051822 Stack et al. Dec 2001 A1
20020013599 Limon et al. Jan 2002 A1
20020013618 Marotta et al. Jan 2002 A1
20020042628 Chin et al. Apr 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020165572 Saadat Nov 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20030004538 Secrest et al. Jan 2003 A1
20030028209 Teoh et al. Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030171739 Murphy et al. Sep 2003 A1
20030171770 Kusleika et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199919 Palmer et al. Oct 2003 A1
20040015224 Armstrong et al. Jan 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040098027 Teoh et al. May 2004 A1
20040098030 Makower et al. May 2004 A1
20040106945 Thramann et al. Jun 2004 A1
20040106977 Sullivan et al. Jun 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040122467 VanTassel et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040143239 Zhou et al. Jul 2004 A1
20040143286 Johnson et al. Jul 2004 A1
20040153119 Kusleika et al. Aug 2004 A1
20040162606 Thompson Aug 2004 A1
20040172056 Guterman et al. Sep 2004 A1
20040172121 Eidenschink et al. Sep 2004 A1
20040181253 Sepetka et al. Sep 2004 A1
20040186562 Cox Sep 2004 A1
20040193206 Gerberding et al. Sep 2004 A1
20040215229 Coyle Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040267346 Shelso Dec 2004 A1
20050010281 Yodfat et al. Jan 2005 A1
20050021077 Chin et al. Jan 2005 A1
20050033408 Jones et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050096728 Ramer May 2005 A1
20050096732 Marotta et al. May 2005 A1
20050107823 Leone et al. May 2005 A1
20050131443 Abdel-Gawwad Jun 2005 A1
20050222605 Greenhalgh Oct 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050288763 Andreas et al. Dec 2005 A1
20060052816 Bates et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060074475 Gumm Apr 2006 A1
20060106421 Teoh May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116714 Sepetka et al. Jun 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060190076 Taheri Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060206199 Churchwell et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060217799 Mailander et al. Sep 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060235464 Avellanet et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241690 Amplatz et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060264907 Eskridge et al. Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060276827 Mitelberg et al. Dec 2006 A1
20060282152 Beyerlein et al. Dec 2006 A1
20060292206 Kim et al. Dec 2006 A1
20060293744 Peckham et al. Dec 2006 A1
20070005125 Berenstein et al. Jan 2007 A1
20070016243 Ramaiah et al. Jan 2007 A1
20070021816 Rudin Jan 2007 A1
20070050017 Sims et al. Mar 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070093889 Wu et al. Apr 2007 A1
20070100415 Licata et al. May 2007 A1
20070106311 Wallace et al. May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070150045 Ferrera Jun 2007 A1
20070162104 Frid Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070191924 Rudakov Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070221230 Thompson et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070233224 Leynov et al. Oct 2007 A1
20070233244 Lopez et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288083 Hines Dec 2007 A1
20070293935 Olsen et al. Dec 2007 A1
20080009934 Schneider et al. Jan 2008 A1
20080021535 Leopold et al. Jan 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080045996 Makower et al. Feb 2008 A1
20080045997 Balgobin et al. Feb 2008 A1
20080051705 Von Oepen et al. Feb 2008 A1
20080058856 Ramaiah et al. Mar 2008 A1
20080065141 Holman et al. Mar 2008 A1
20080065145 Carpenter Mar 2008 A1
20080097495 Feller, III et al. Apr 2008 A1
20080109063 Hancock et al. May 2008 A1
20080114391 Dieck et al. May 2008 A1
20080114436 Dieck et al. May 2008 A1
20080114439 Ramaiah et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080125806 Mazzocchi et al. May 2008 A1
20080125848 Kusleika et al. May 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080140177 Hines Jun 2008 A1
20080154286 Abbott et al. Jun 2008 A1
20080195139 Donald et al. Aug 2008 A1
20080219533 Grigorescu Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080243226 Fernandez et al. Oct 2008 A1
20080249562 Cahill Oct 2008 A1
20080262598 Elmaleh Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080319533 Lehe Dec 2008 A1
20090025820 Adams Jan 2009 A1
20090069806 De La Mora Levy et al. Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090118811 Moloney May 2009 A1
20090125094 Rust May 2009 A1
20090143849 Ozawa et al. Jun 2009 A1
20090143851 Paul, Jr. Jun 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090204145 Matthews Aug 2009 A1
20090210047 Amplatz et al. Aug 2009 A1
20090216307 Kaufmann et al. Aug 2009 A1
20090228029 Lee Sep 2009 A1
20090228093 Taylor et al. Sep 2009 A1
20090259202 Leeflang et al. Oct 2009 A1
20090264914 Riina et al. Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287294 Rosqueta et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090318941 Sepetka et al. Dec 2009 A1
20090318948 Linder Dec 2009 A1
20100004726 Hancock et al. Jan 2010 A1
20100004761 Flanders et al. Jan 2010 A1
20100023048 Mach Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100030220 Truckai et al. Feb 2010 A1
20100036390 Gumm Feb 2010 A1
20100042133 Ramzipoor et al. Feb 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100087908 Hilaire et al. Apr 2010 A1
20100094335 Gerberding et al. Apr 2010 A1
20100131002 Connor et al. May 2010 A1
20100152767 Greenhalgh et al. Jun 2010 A1
20100185271 Zhang Jul 2010 A1
20100222802 Gillespie, Jr. et al. Sep 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100268260 Riina et al. Oct 2010 A1
20100274276 Chow et al. Oct 2010 A1
20100312270 McGuckin, Jr. et al. Dec 2010 A1
20100331948 Turovskiy et al. Dec 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110054519 Neuss Mar 2011 A1
20110082493 Samson et al. Apr 2011 A1
20110106234 Grandt May 2011 A1
20110144669 Becking et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110184452 Huynh et al. Jul 2011 A1
20110184453 Levy et al. Jul 2011 A1
20110196415 Ujiie et al. Aug 2011 A1
20110202085 Loganathan et al. Aug 2011 A1
20110208227 Becking Aug 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110276120 Gilson et al. Nov 2011 A1
20110313447 Strauss et al. Dec 2011 A1
20110319926 Becking et al. Dec 2011 A1
20120041470 Shrivastava et al. Feb 2012 A1
20120065720 Strauss et al. Mar 2012 A1
20120101561 Porter Apr 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120165803 Bencini et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120226343 Vo et al. Sep 2012 A1
20120245674 Molaei et al. Sep 2012 A1
20120245675 Molaei et al. Sep 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120316598 Becking et al. Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330347 Becking et al. Dec 2012 A1
20130018451 Grabowski et al. Jan 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130066360 Becking et al. Mar 2013 A1
20130085522 Becking et al. Apr 2013 A1
20130092013 Thompson et al. Apr 2013 A1
20130123830 Becking et al. May 2013 A1
20130211495 Halden et al. Aug 2013 A1
20130233160 Marchand et al. Sep 2013 A1
20130239790 Thompson et al. Sep 2013 A1
20130245667 Marchand et al. Sep 2013 A1
20130245670 Fan Sep 2013 A1
20130268053 Molaei Oct 2013 A1
20130274862 Cox et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
20130304179 Bialas et al. Nov 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005713 Bowman Jan 2014 A1
20140128905 Molaei May 2014 A1
Foreign Referenced Citations (70)
Number Date Country
2607529 Apr 2008 CA
101472537 Jul 2009 CN
1283434 Nov 1968 DE
102008028308 Apr 2009 DE
102010050569 May 2012 DE
102011011510 Aug 2012 DE
743047 Nov 1996 EP
775470 May 1997 EP
855170 Jul 1998 EP
1621148 Feb 2006 EP
1637176 Mar 2006 EP
1752112 Feb 2007 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2279023 Feb 2011 EP
2363075 Sep 2011 EP
2496299 Sep 2012 EP
2675402 Dec 2013 EP
2556210 Apr 1988 FR
2890306 Mar 2007 FR
11-506686 Jun 1999 JP
2003-520103 Jul 2003 JP
2003-524434 Aug 2003 JP
2004-049585 Feb 2004 JP
2005-522266 Jul 2005 JP
2006-506201 Feb 2006 JP
2008-541832 Nov 2008 JP
4673987 Apr 2011 JP
WO-8800813 Feb 1988 WO
WO-9601591 Jan 1996 WO
WO-9726939 Jul 1997 WO
WO-9903404 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO-9908607 Feb 1999 WO
WO-9908743 Feb 1999 WO
WO-9940873 Aug 1999 WO
WO-9962432 Dec 1999 WO
WO-0057815 Oct 2000 WO
WO-0193782 Dec 2001 WO
WO-02000139 Jan 2002 WO
WO-02071977 Sep 2002 WO
WO-03037191 May 2003 WO
WO-2005117718 Dec 2005 WO
WO-2006026744 Mar 2006 WO
WO-2006034166 Mar 2006 WO
WO-2006052322 May 2006 WO
WO-2006091891 Aug 2006 WO
WO-2006119422 Nov 2006 WO
WO-2007047851 Apr 2007 WO
WO-2007076480 Jul 2007 WO
WO-2007095031 Aug 2007 WO
WO-2007121405 Oct 2007 WO
WO-2008022327 Feb 2008 WO
WO-2008109228 Sep 2008 WO
WO-2008151204 Dec 2008 WO
WO-2008157507 Dec 2008 WO
WO-2009076515 Jun 2009 WO
WO-2009132045 Oct 2009 WO
WO-2009134337 Nov 2009 WO
WO-2009135166 Nov 2009 WO
WO-2010028314 Mar 2010 WO
WO-2010030991 Mar 2010 WO
WO-2010147808 Dec 2010 WO
WO-2011057002 May 2011 WO
WO-2011057277 May 2011 WO
WO-2011130081 Oct 2011 WO
WO-2011153304 Dec 2011 WO
WO-2012068175 May 2012 WO
WO-2012112749 Aug 2012 WO
WO-2012166804 Dec 2012 WO
Non-Patent Literature Citations (6)
Entry
Hill, et al., “Initial Results of the AMPLATZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004.
Ronnen, “AMPLATZER Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007.
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040.
U.S. Appl. No. 13/826,298, filed Mar. 14, 2013.
U.S. Appl. No. 13/795,556, filed Mar. 12, 2013.
U.S. Appl. No. 13/669,652, filed Nov. 6, 2012.
Related Publications (1)
Number Date Country
20140172001 A1 Jun 2014 US
Provisional Applications (1)
Number Date Country
61441845 Feb 2011 US
Continuations (1)
Number Date Country
Parent PCT/US2012/024747 Feb 2012 US
Child 13962267 US